Murepavadin

Drug Profile

Murepavadin

Alternative Names: POL 7080; RG 7929

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor
  • Class Antibacterials; Cyclic peptides
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pseudomonal infections
  • Phase I Gram-negative infections

Most Recent Events

  • 01 Jun 2017 Polyphor plans a phase III program for Pseudomonal infections, in the second half of 2017
  • 25 Apr 2017 Efficacy and pharmacokinetics data from a phase II trial in Pseudomonal infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
  • 25 Apr 2017 Pharmacokinetic results from a phase I drug-drug interaction trial in Healthy volunteers presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top